Previous 10 |
Gainers: 1Life Healthcare ( ONEM ) +69% . Tabula Rasa HealthCare ( TRHC ) +52% . Vertical Aerospace ( EVTL ) +41% . Moon Lake Immuno therapeutics ( MLTX ) +32% . Altice USA ( ATUS ) +26% . Kaltura ( KLTR ) +22% . ...
Super Micro Computer ( SMCI ) +20% on better-than-expected Q4 prelim results. ToughBuilt Industries ( TBLT ) +16% . MoonLake Immunotherapeutics ( MLTX ) +14% . Visionary Education Technology Holdings ( VEDU ) +12% . Olema Pharmaceuti...
Cowen analyst Phil Nadeau initiated coverage of MoonLake Immunotherapeutics ( MLTX ) with an Outperform rating. The company is developing sonelokimab in inflammatory diseases and Phase 2 data in psoriasis suggest improved safety and efficacy compared to traditional anti-IL-17...
Gainers: Helius Medical Technologies (HSDT) +57%. Tonix Pharmaceuticals TNXP +49%. NeuroOne Medical Technologies (NMTC) +16%. Oncternal Therapeutics (ONCT) +16%. Butterfly Network (BFLY) +15%. Losers: Enochian Biosciences ENOB -37%. Icosavax ...
MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company that specializes in therapies for inflammatory skin and joint diseases, saw its shares jump 41.1% on Tuesday. The stock closed at $6.38 on Friday, then opened at $7.55 on Tuesday after the Memorial Da...
Gainers: TherapeuticsMD (TXMD) +355%. MoonLake Immunotherapeutics (MLTX) +24%. Gritstone bio (GRTS) +18%. Nurix Therapeutics (NRIX) +10%. DexCom (DXCM) +9%. Losers: Outlook Therapeutics (OTLK) -54%. Elevation Oncology (ELEV) -18%. SIGA Technologies (SIGA) -1...
Switzerland-based MoonLake Immunotherapeutics (NASDAQ:MLTX) said the first patient was dosed at a U.S. site of its global phase 2 trial of investigational Nanobody sonelokimab to treat patients with moderate-to-severe hidradenitis suppurativa (HS). HS is a condition causing sma...
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa First Phase 2 trial in hidradenitis suppurativa using the higher clinical response level of HiSCR75 as the primary endpoint ...
News, Short Squeeze, Breakout and More Instantly...
MoonLake Immunotherapeutics Company Name:
MLTX Stock Symbol:
NASDAQ Market:
2024-06-23 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical,...
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New...